The clock for profitable partnership for Revance started ticking after Sakura-3 data came out in Q4’18. And you add to that JPM19 breakfast meeting followed by showcasing ‘ground breaking’ data, you have perfect storm for big pharma to take notice. No one apparently has done so far or at-least expressed interest, looks like.
Otherwise no reason for Dan to raise funds at least until BLA is filed.
I am more convinced partnership for NA market is unlikely this year. I hope to be wrong.
P.S: Reduced my holdings significantly today. I am ok to buy higher if things turn up.
News 
Market Data 
Discover 
